1-benzyl-1H-imidazole-2-carbonitrile | 46323-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-benzyl-1H-imidazole-2-carbonitrile
• 英文别名: 1-(Phenylmethyl)-1H-imidazole-2-carbonitrile；1H-Imidazole-2-carbonitrile, 1-(phenylmethyl)-；1-benzylimidazole-2-carbonitrile
• CAS: 46323-27-7
• 化学式: C₁₁H₉N₃
• 分子量: 183.213
• InChiKey: IYJCCWWFXUVDEC-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  130 °C(Press: 0.4 Torr)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  41.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzyl-1H-imidazole-2-carbonitrile 在 sodium 作用下， 以 氨 为溶剂， 以24%的产率得到1H-咪唑-2-腈
  参考文献：
  名称：

  N-cyano-N′-alkylimidazolium ylids as novel intermediates to 2-cyanoimidazoles

  摘要：

  DOI：

  10.1016/s0040-4039(01)84575-5
• 作为产物：
  描述：

  在 三乙胺 作用下， 以 乙腈 为溶剂， 以83%的产率得到1-benzyl-1H-imidazole-2-carbonitrile
  参考文献：
  名称：

  N-cyano-N′-alkylimidazolium ylids as novel intermediates to 2-cyanoimidazoles

  摘要：

  DOI：

  10.1016/s0040-4039(01)84575-5

文献信息

• Cyanogen Bromide-Dimethylaminopyridine (CAP): A Convenient Source of<i>Positive Cyanide</i>for the Synthesis of 2-Cyanoimidazoles
  作者：Jeffrey P. Whitten、James R. Mccarthy、Donald P. Matthews

  DOI：10.1055/s-1988-27609

  日期：——

  Dimethylaminopyridine activates cyanogen bromide towards C-C bond formation by forming 1-cyano-4-dimethylaminopyridinium bromide. The latter serves as a convenient reagent for the synthesis of 2-cyanoimidazoles.

  二甲基氨基吡啶通过形成1-氰基-4-二甲基氨基吡啶溴化物激活溴化氰以形成C-C键。后者作为合成2-氰基咪唑的方便试剂。
• 2,2'-bi-1H-imidazoles
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05147863A1

  公开（公告）日：1992-09-15

  This invention relates to novel derivatives of 2,2'-bi-1H-imidazoles, to the processes and intermediates used in their preparation, to their ability to exert the pharmacologic effects of lowering high blood pressure and of increasing heart contractile force and to their use as chemotherpauetic agents useful in treating cardiac insufficiency and hypertension.

  本发明涉及2,2'-双-1H-咪唑醇的新颖衍生物，涉及其制备过程和中间体，以及其具有降低高血压和增加心脏收缩力的药理作用，并将其用作治疗心脏不全和高血压的化疗药物。
• Synthesis and cardiotonic activity of novel biimidazoles
  作者：Donald P. Matthews、James R. McCarthy、Jeffrey P. Whitten、Philip R. Kastner、Charlotte L. Barney、Franklin N. Marshall、Marcia A. Ertel、Therese Burkhard、Philip J. Shea、Takashi Kariya

  DOI：10.1021/jm00163a052

  日期：1990.1

  A series of substituted 2,2'-bi-1H-imidazoles and related analogues was synthesized and evaluated for inotropic activity. Structure-activity relationship studies based on a nonclassical bioisosteric approach indicated the necessity of a cyano group on one of the imidazole rings to obtain the desired pharmacological profile. 4(5)-Cyano-2,2'-bi-1H-imidazole (15a) was the most potent inotropic agent in

  合成了一系列取代的2,2'-bi-1H-咪唑和相关类似物，并评估了其正性肌力。基于非经典生物等位线方法的结构活性关系研究表明，咪唑环之一上的氰基必须具有所需的药理特性。4（5）-Cyano-2,2'-bi-1H-咪唑（15a）是该系列中最有效的正性肌力药。在麻醉狗中，0.16 mg / kg iv时左心室dP / dt增加25％（ED25％= 0.16 mg / kg），在1 mg / kg iv时左心室收缩力增加60％。化合物15a是分离自犬心的IV型环状核苷酸磷酸二酯酶的良好抑制剂，具有与氨力农相似的效力。5'-cyano-2,4'-bi-1H-咪唑（44）和4-cyano-2,4' -bi-1H-咪唑（48）具有正性肌力活性。另外，两种可能的1,1'-二甲基氰基-2,2'-bi-1H-咪唑（24和25）是不活泼的，表明酸性NH和氰基对于正性肌力活性至关重要。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20210292351A1

  公开（公告）日：2021-09-23

  Disclosed are platinum or palladium complexes featuring tetradentate ligands with at least one side that has an NN binding motif are disclosed. The disclosed organometallic compounds have a structure of where M is Pt or Pd. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

  公开了具有至少一个具有NN结合基团的四齿配体的铂或钯配合物。所述的有机金属化合物具有以下结构，其中M为Pt或Pd。还提供了包含这些有机金属化合物的配方。还提供了利用这些有机金属化合物的OLED和相关消费产品。
• Novel derivatives of imidazole, and pharmaceutical compositions
  申请人：Hoechst Aktiengesellschaft

  公开号：US04152440A1

  公开（公告）日：1979-05-01

  A compound of one of formulae (I) and (II) (of formula sheet) wherein R.sup.1 represents a radical selected from the group consisting of hydrogen alkyl containing up to 6 carbon atoms and being unsubstituted or substituted by at least one of the groups alkoxy and phenylalkoxy containing up to 4 carbon atoms in the alkoxy moiety; aryl or aralkyl each containing from 1 to 4 carbon atoms in the alkyl moiety and being unsubstituted or substituted by at least one substituent selected from the group consisting of alkyl, alkoxy and haloalkyl containing up to 4 carbon atoms, halogen and nitro; a 5- or 6-membered heteroaromatic ring containing up to 2 hetero atoms chosen from O,N and S, at most one of which is different from nitrogen; an alkyl group containing from 1 to 4 carbon atoms substituted by such a heteroaromatic ring; R.sup.2 and R.sup.3, which are the same or different, each represents a hydrogen atom or, alkyl containing up to 4 carbon atoms and being unsubstituted or substituted by at least one substituent selected from the group consisting of alkyl, alkoxy and haloalkyl containing up to 4 carbon atoms, halogen and nitro; taken together R.sup.2 and R.sup.3 alternatively represent a --CH.dbd.CH--CH.dbd.CH-- group which is unsubstituted or substituted by a substituent selected from the group consisting of alkyl, alkoxy and haloalkyl, each containing up to 4 carbon atoms, halogen and nitro; R.sup.4 is selected from the group consisting of hydrogen alkyl, aryl and aralkyl containing up to 4 carbon atoms in each alkyl moiety; and A represents a single bond or alkylene containing from 1 to 6 carbon atoms; with the proviso that R.sup.1 is other than a hydrogen atom or methyl group when A represents a single bond and R.sup.2 and R.sup.3 taken together represent an unsubstituted --CH.dbd.CH--CH.dbd.CH-- group; physiologically acceptable salts thereof, a synthesis therefor and a pharmaceutical composition containing it.

  一种由公式（I）和（II）中的其中一个组成的化合物，其中R.sup.1代表从以下组中选择的基团：氢、含有最多6个碳原子的烷基，未取代或被取代为含有最多4个碳原子的烷氧基和苯基烷氧基中至少一种基团; 芳基或芳基烷基，烷基部分含有1至4个碳原子，未取代或被取代为含有最多4个碳原子的烷基、烷氧基和卤代烷基、卤素和硝基中至少一种取代基; 含有最多2个由O、N和S选择的杂原子的5-或6-成员杂芳环，其中最多一个与氮不同; 含有1至4个碳原子的烷基基团，被这样的杂芳环取代; R.sup.2和R.sup.3，相同或不同，各代表一个氢原子或，含有最多4个碳原子的烷基，未取代或被取代为含有最多4个碳原子的烷基、烷氧基和卤代烷基、卤素和硝基中至少一种取代基; R.sup.2和R.sup.3结合在一起时，或者代表一个未取代或被取代为含有最多4个碳原子的烷基、烷氧基和卤代烷基、卤素和硝基中至少一种取代基的--CH.dbd.CH--CH.dbd.CH--基团; R.sup.4选自氢、烷基、芳基和芳基烷基，每个烷基部分含有最多4个碳原子; A代表单键或含有1至6个碳原子的烷基; 但R.sup.1不是氢原子或甲基基团，当A代表单键且R.sup.2和R.sup.3结合在一起代表一个未取代的--CH.dbd.CH--CH.dbd.CH--基团时; 其生理上可接受的盐，其合成方法以及含有它的药物组合物。